第5部（モジュール5）　臨床試験報告書　添付資料一覧

5.4　参考文献

添付資料番号	タイトル	著者	報種類	掲載誌
-	Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a large observational inception study.	Bukhari MA, Wiles NJ, Lunt M, et al.	海外	Arthritis Rheum. 2003;48(1):46–53.
-	Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumor necrosis factor inhibitors: a randomized Phase 3 trial.	Burmester GR, Blanco R, Charles-Schoeman C, et al.	海外	Lancet. 2013;381(9865):451-60.
-	Adalimumab: long-term safety in 23,458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease.	Burmester GR, Panaccione R, Gordon KB, et al.	海外	Ann Rheum Dis. 2013,72(4):517-24.
-	Emerging cells and cytokine targets in rheumatoid arthritis.	Burmester GR, Feist E, Dorner T.	海外	Nat Rev Rheumatol. 2014;10(2):77-88.
-	Increased risk of tuberculosis in patients with rheumatoid arthritis.	Carmona L, Hernández-García C, Vadillo C, et al.	海外	J Rheumatol. 2003;30(7):1436-9.
-	FDA Medical Review December 11, 2009 Actemra® (tocilizumab) injection	-	海外	-
-	Clinical pharmacology and biopharmaceutics review(s)—tofacitinib.	Center for Drug Evaluation and Research (CDER).	海外	Silver Spring. 2011.

第5部（モジュール5）　臨床試験報告書　添付資料一覧

5.4　参考文献

添付資料番号	タイトル	著者	報種類	掲載誌
-	FDA Medical Review Reference ID: 3151008, Xeljanz® (tofacitinib) tablets. 2012	-	海外	-
-	FDA Clinical Review Reference ID: 3994713, Kevzara® (sarilumab) injection. 2017	-	海外	-
-	Clinical pharmacology and biopharmaceutics review(s)—baricitinib.	Center for Drug Evaluation and Research (CDER).	海外	Silver Spring. 2018.
-	Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib.	Charles-Schoeman C, Fleischmann R, Davignon J, et al.	海外	Arthritis Rheumatol. 2015;67(3):616-25.
-	Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs.	Charles-Schoeman C, Burmester G, Nash P, et al.	海外	Ann Rheum Dis. 2016;75(7):1293-301.
-	Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implicaitons for the rheumatologist.	Charles-Schoeman C, Gonzalez-Gay MA, Kaplan I, et al.	海外	Semin Arthritis Rheum. 2016;46(1):71–80.
-	Future therapeutic targets in rheumatoid arthritis?	Cheung TT and McInnes IB.	海外	Semin Immunopathol. 2017;39(4):487-500

第5部（モジュール5）　臨床試験報告書　添付資料一覧

5.4　参考文献

添付資料番号	タイトル	著者	報種類	掲載誌
-	Guideline on Clinical Investigation of Medicinal Products for the Treatment of Rheumatoid Arthritis. 2017.	Committee for Medicinal Products for Human Use (CHMP).	海外	-
-	An atypical varicella exanthem associated with the use of infliximab.	Choi HJ, Kim MY, Kim HO, Park YM.	海外	Int J Dermatol. 2006;45(8):999.
-	The risk of pulmonary embolism and deep vein thrombosis in rheumatoid arthritis: a UK population-based outpatient cohort study.	Choi HK, Rho YH, Zhu Y, et al.	海外	Ann Rheum Dis. 2013;72(7):1182-7.
-	Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions.	Choy E, Sattar N.	海外	Ann Rheum Dis. 2009;68(4):460-9.
-	Rheumatoid arthritis increases the risk of deep vein thrombosis and pulmonary thromboembolism: a nationwide cohort study.	Chung WS, Peng CL, Lin CL, et al.	海外	Ann Rheum Dis. 2014; 73(10):1774-80.
-	Long term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from global clinical trials.	Cohen SB, Tanaka Y, Mariette X, et al.	海外	Ann Rheum Dis. 2017;76(7):1253-62.
-	Is Infection an Independent Risk Factor for Venous Thromboembolism? A Population-Based, Case-Control Study.	Cohoon KP, Ashrani AA, Crusan DJ, et al.	海外	Am J Med. 2018;131(3):307-16.e2.

第5部（モジュール5）　臨床試験報告書　添付資料一覧

5.4　参考文献

添付資料番号	タイトル	著者	報種類	掲載誌
-	Current understanding of rheumatoid arthritis therapy.	Colmegna I, Ohata BR, Menard HA.	海外	Clin Pharmacol Ther. 2012;91(4):607-20.
-	Effects of biologic disease-modifying anti-rheumatic drugs on the radiographic progression of rheumatoid arthritis: a systematic literature review.	Combe B, Lula S, Boone C, et al.	海外	Clin Exp Rheumatol. 2018;36(4):658-67.
-	Elevated Liver Enzyme Tests Among Rheumatoid Arthritis and Psoriatic Arthritis Patients treated with Methotrexate and/orLeflunomide.	Curtis JR, Beukelman T, Onofrei A, et al.	海外	Ann Rheum Dis. 2010; 69(1): 43–7.
-	Factors Associated With Gastrointestinal Perforation In A Cohort Of Patients With Rheumatoid Arthritis.	Curtis JR, Lanas A, John A, et al.	海外	Arthritis Care Res. 2012 Dec;64(12):1819-28
-	Epidemiology and risk factors for venous thrombosis.	Cushman M.	海外	Semin Hematol. 2007;44(2): 62-9.
-	Mortality in rheumatoid arthritis over the last fifty years: systematic review and meta-analysis.	Dadoun S, Zeboulon-Ktorza N, Combescure C.	海外	Joint Bone Spine. 2013;80(1) 29-33.
-	Prevalence of clinical venous thromboembolism in the USA: current trends and future projections.	Deitelzweig SB, Johnson BH, Lin J, et al.	海外	Am J Hematol. 2011;86(2):217-20.

第5部（モジュール5）　臨床試験報告書　添付資料一覧

5.4　参考文献

添付資料番号	タイトル	著者	報種類	掲載誌
-	Comparative Risk of Venous Thromboembolism with Tofacitinib Versus Tumor Necrosis Factor Inhibitors: A Cohort Study of Rheumatoid Arthritis Patients. abstract L09.	Desai RJ, Pawar A, Weinblatt ME.	海外	Arthritis Rheumatol. 2018;70 (Suppl 10).
-	Effects of interleukin-6 (IL-6) and an anti-IL-6 monoclonal antibody on drug-metabolizing enzymes in human hepatocyte culture.	Dickmann LJ, Patel SK, Rock DA, et al.	海外	Drug Metab Dispos. 2011;39(8):1415–22.
-	Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study.	Doran MF, Crowson CS, Pond GR, et al.	海外	Arthritis Rheum. 2002:46(9):2287-93
-	Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study.	Dougados M, van der Heijde D, Chen Y, et al.	海外	Ann Rheum Dis. 2017;76:88-95.
-	Global Burden of Tuberculosis Estimated Incidence, Prevalence, and Mortality by Country.	Dye C, Scheele S, Dolin P, et al.	海外	JAMA 1999-Vol 282 No.7.
-	FDA Briefing Document Arthritis Advisory Committee Meeting Summary of Resubmission (Baricitinib tablets)April 23, 2018	-	海外	-
-	Olumiant [package insert]. Indianapolis, IN; Eli Lilly, 2018.	-	海外	-

第5部（モジュール5）　臨床試験報告書　添付資料一覧

5.4　参考文献

添付資料番号	タイトル	著者	報種類	掲載誌
-	EMA. Guideline on the investigation of drug interactions. 21 June 2012.	-	海外	-
-	EMA. Guideline on quality of oral modified release products. 20 March 2014.	-	海外	-
-	Why is there persistent disease despite biological therapy? Importance and early intervention.	Emery P.	海外	Arthritis Res Ther. 2014;16(3):115.
-	Venous thrombosis in the elderly: incidence, risk factors and risk groups.	Engbers MJ, van Hylckama Vlieg A, Rosendaal FR.	海外	J Thromb Haemost. 2010;8(10):2105-12.
-	Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications.	England BR, Thiele GM, Anderson DR, et al.	海外	BMJ 2018; 361:K1036.
-	Biological vs. conventional combination treatment and work loss in early rheumatoid arthritis: a randomized trial.	Eriksson JK, Neovius M, Bratt J, et al.	海外	JAMA Intern Med. 2013;173(15):1407–14.
-	Assessing the risk of recurrent venous thromboembolism--a practical approach.	Fahrni J, Husmann M, Gretener SB, et al.	海外	Vasc Health Risk Manag. 2015;11:451-9.

第5部（モジュール5）　臨床試験報告書　添付資料一覧

5.4　参考文献

添付資料番号	タイトル	著者	報種類	掲載誌
-	FDA Guidance for Industry: Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/In Vivo Correlations. 1997	-	海外	-
-	Food and Drug Administration (FDA) Guidance for Industry: Clinical Development Programs for Drugs, Devices, and Biological Products for the Treatment of Rheumatoid Arthritis (RA), February 1999	-	海外	-
-	FDA Guidance for Industry. Pharmacokinetics in Patients with Impaired Renal Function — Study Design, Data Analysis, and Impact on Dosing and Labeling. 2010.	-	海外	-
-	FDA Guidance for Industry: Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs —General Considerations. 2014.	-	海外	-
-	FDA Guidance Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System Guidance for Industry. 2017.	-	海外	-
-	FDA. Clinical Drug Interaction Studies - Study Design, Data Analysis, and Clinical Implications. Guidance for Industry. 2017.	-	海外	-
-	FDA Guidance Bioanalytical Method Validation Guidance for Industry 2018	-	海外	-

第5部（モジュール5）　臨床試験報告書　添付資料一覧

5.4　参考文献

添付資料番号	タイトル	著者	報種類	掲載誌
-	Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis.	Fleischmann R, Kremer J, Cush J, et al.	海外	N Engl J Med. 2012;367(6):495-507.
-	A randomized, double-blind, placebo-controlled, twelve-week, dose-ranging study of decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with active rheumatoid arthritis.	Fleischmann RM, Damjanov NS, Kivitz AJ et al.	海外	Arthritis & rheumatology 2015;67(2): 334-43.
-	Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.	Fleischmann R, Mysler E, Hall S.	海外	Lancet. 2017;390(10093):457-68.
-	Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment.	Fleischmann R, Schiff M, van der Heijde D, et al.	海外	Arthritis Rheumatol. 2017;69(3):506-17.
-	The arrival of JAK inhibitors: advancing the treatment of immune and hematologic disorders.	Furumoto Y, Gadina M.	海外	BioDrugs 2013; 27(5):431-8
-	Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years.	Gabriel SE, Crowson CS, Kremers HM, et al.	海外	Arthritis Rheum. 2003;48(1):54-8.
-	Cardiovascular morbidity and mortality in rheumatoid arthritis.	Gabriel SE.	海外	Am J Med. 2008;121(10 Suppl 1):S9–14.

第5部（モジュール5）　臨床試験報告書　添付資料一覧

5.4　参考文献

添付資料番号	タイトル	著者	報種類	掲載誌
-	Scientific white paper on concentration-QTc modeling.	Garnett C, Bonate PL, Dang Q, et al.	海外	J Pharmacokinet Pharmacodyn. 2018;45(3):383-97.
-	Baricitinib in Patients with Refractory Rheumatoid Arthritis.	Genovese MC, Kremer J, Zamani O, et al.	海外	N Engl J Med. 2016;374(13):1243-52.
-	Janus kinases in immune cell signaling.	Ghoreschi K, Laurence A, O'Shea JJ.	海外	Immunol Rev. 2009;228(1):273-87.
-	Overview of epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis.	Gibofsky A.	海外	Am J Manag Care. 2012;18(13 Suppl):S295-302.
-	Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial.	Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al.	海外	Ann Intern Med. 2007;146(6):406–15.
-	Clinical features of early, progressive and late disease. In: Klippel JH, Dieppe PA, editors.	Gordon DA, Hastings DE.	海外	Rheumatology. 2nd ed. London: Mosby; 1998;5(3):1-14.
-	Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial.	Grigor C, Capell H, Stirling A, et al.	海外	Lancet. 2004;364(9430):263-9.

第5部（モジュール5）　臨床試験報告書　添付資料一覧

5.4　参考文献

添付資料番号	タイトル	著者	報種類	掲載誌
-	Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease.	Gupta G, Lautenbach E, Lewis JD.	海外	Clin Gastroenterol Hepatol. 2006;4(12):1483-90.
-	Prevention of Herpes Zoster. Recommendations of the Advisory Committee on Immunization Practices (ACIP).	Harpaz R, Ortega-Sanchez, Seward J F, et al.	海外	MMWR. 2008;57(05):1-30.
-	Epidemiology of Venous Thromboembolism.	Heit, J.A.	海外	Nat Rev Cardiol. 2015; 12(8): 464–74.
-	Reproducibility of QTc interval changes after meal intake.	Hnatkova K, Kowalski D, Keirns JJ, et al.	海外	J Electrocardiol. 2015;48(2):194-202.
-	Transporters and drug therapy: implications for drug disposition and disease.	Ho RH, Kim RB.	海外	Clin Pharmacol Ther. 2005;78(3):260-77.
-	Can a computerized format replace a paper form in PRO and HRQL evaluation? Psychometric testing of the computer-assisted LCSS instrument (eLCSS-QL).	Patricia J. Hollen, et al.	海外	Support Care Cancer (2013) 21:165–172.
-	Risk of venous thromboembolism in patients with rheumatoid arthritis and association with disease duration and hospitalization.	Holmqvist ME, Neovius M, Eriksson J, et al.	海外	JAMA. 2012; 308 (13):1350-6.

第5部（モジュール5）　臨床試験報告書　添付資料一覧

5.4　参考文献

添付資料番号	タイトル	著者	報種類	掲載誌
-	Secular trends in occurrence of acute venous thromboembolism: the Worcester VTE study (1985–2009).	Huang W, Goldberg RJ, Anderson FA, et al.	海外	Am. J. Med. 2014; 127:829.e5–839.e5
-	Mortality trends in patients with early rheumatoid arthritis over 20 years: results from the Norfolk Arthritis Register.	Humphreys JH, Warner A, Chipping J, et al.	海外	Arthritis Care Res (Hoboken). 2014;66(9):1296-301.
-	Progress in understanding the safety and efficacy of Janus kinase inhibitors for treatment of rheumatoid arthritis.	Iwata S and Tanaka Y.	海外	Expert Rev Clin Immunol. 2016;12(10):1047-57.
-	Comparative study of electronic vs. paper VAS ratings: a randomized, crossover trial using healthy volunteers.	Robert N. Jamison, et al.	海外	Pain 99 (2002) 341–347.
-	関節リウマチ診療ガイドライン2014. : p 44-73	日本リウマチ学会.	国内	メディカルレビュー社;2014
-	Increase of body mass index in a tight controlled methotrexate-based strategy with prednisone in early rheumatoid arthritis: side-effect of the prednisone or better control of disease activity?	Jurgens MS, Jacobs JW, Greenen R, et al.	海外	Arthritis Care Res (Hoboken) 2013; 65(1): 88-93.
-	Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment.	Kalden JR, Schulze-Koops H.	海外	Nat Rev Rheumatol. 2017 ;13(12):707-18.

第5部（モジュール5）　臨床試験報告書　添付資料一覧

5.4　参考文献

添付資料番号	タイトル	著者	報種類	掲載誌
-	Fetal wastage in patients with rheumatoid arthritis.	Kaplan D.	海外	J Rheumatol. 1986;13(5):875-7.
-	Management of anticoagulation before and after elective surgery.	Kearon C, Hirsh J.	海外	N Engl J Med. 1997;336(21):1506-11.
-	Neurological and ophthalmological manifestations of varicella zoster virus.	Kedar S, Jayagopal LN, Berger JR.	海外	J Neuroophthalmol. 2018 Sep 1. [Epub ahead of print].
-	Risk of venous thromboembolism in patients with rheumatoid arthritis.	Kim SC, Schneeweiss S, Liu J.	海外	Arthritis Care Res (Hoboken). 2013;65(10):1600-7.
-	Severe herpes zoster after infliximab infusion.	Kinder A, Stephens S, Mortimer N, et al.	海外	Postgrad Med J. 2004;80(939):26.
-	Risk of venous thromboembolism in patients with inflammatory bowel disease.	Koutroumpakis EI, Tsiolakidou G, Koutroubakis IE.	海外	Semin Thromb Hemost. 2013;39(5):461-8.
-	Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis.	Krause D, Schleusser B, Herborn G, et al.	海外	Arthritis Rheum. 2000;43(1):14-21.

第5部（モジュール5）　臨床試験報告書　添付資料一覧

5.4　参考文献

添付資料番号	タイトル	著者	報種類	掲載誌
-	Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial.	Kremer J, Li ZG, Hall S, et al.	海外	Ann Interim Med. 2013;159(4):253-61.
-	Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial.	Kremer JM, Kivitz AJ, Simon-Campos JA, et al.	海外	Arthritis Res Ther. 2015; 17(1): 95.
-	A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy.	Kremer JM, Emery P, Camp HS, et al.	海外	Arthritis Rheumatol. 2016;68(12): 2867-77.
-	IL-6 stimulates intestinal epithelial proliferation and repair after injury.	Kuhn KA, Manieri NA, Liu TC, et al.	海外	PLoS One. 2014;9(12):e114195.
-	Serum C-reactive protein increases the risk of venous thromboembolism: a prospective study and meta-analysis of published prospective evidence.	Kunutsor SK, Seidu S, Blom AW, et al.	海外	Eur J Epidemiol. 2017;32(8):657-67.
-	Patterns of medication use during pregnancy in rheumatoid arthritis.	Kuriya B, Hernández-Díaz S, Liu J, et al.	海外	Arthritis Care Res (Hoboken). 2011;63(5):721-8.
-	Incidence and prevalence of major adverse cardiovascular events in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis.	Lauper K, Courvoisier DS, Chevallier P, et al.	海外	Arthritis Care Res (Hoboken). 2018;70(12):1756–63

第5部（モジュール5）　臨床試験報告書　添付資料一覧

5.4　参考文献

添付資料番号	タイトル	著者	報種類	掲載誌
-	Effect of CP-690,550, an orally active janus kinase inhibitor, on renal function in healthy adult volunteers.	Lawendy N, Krishnaswai S, Wang R, et al.	海外	J Clin Pharmacol. 2009;49(4):423-9.
-	Management of neutropenia in patients with rheumatoid arthritis.	Lazaro E, Morel J.	海外	Joint Bone Spine. 2015. 82:235–9.
-	Herpes zoster encephalomyelitis associated with low dose methotrexate for rheumatoid arthritis.	Lyon CC, Thompson D.	海外	J Rheumatol. 1997;24(3):589-91.
-	Cardiovascular death in rheumatoid arthritis: a population-based study.	Maradit-Kremers H, Nicola PJ, Crowson CS, et al.	海外	Arthritis Rheum. 2005;52(3):722-32.
-	Rheumatoid cachexia revisited: A metabolic co-morbidity in rheumatoid arthritis.	Masuko K.	海外	Front Nutr 2014; 1:20.
-	The pathogenesis of rheumatoid arthritis.	McInnes IB, Schett G.	海外	N Engl J Med. 2011;365(23):2205-19.
-	Small-molecule therapeutics in rheumatoid arthritis: scientific rationale, efficacy and safety.	Meier FMP, McInnes IB.	海外	Best Pract Res Clin Rheumatol. 2014;28(4):605-24.

第5部（モジュール5）　臨床試験報告書　添付資料一覧

5.4　参考文献

添付資料番号	タイトル	著者	報種類	掲載誌
-	Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis.	Miloslavsky EM, Naden RP, Bijlsma JW, et al.	海外	Ann Rheum Dis. 2017;76(3):543-6.
-	Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial.	Mottonen T, Hannonen P, Leirisalo-Repo M, et al for the FIN-RACo Trial Group.	海外	Lancet. 1999;353(9164): 1568–73.
-	The Jak-STAT signaling pathway: input and output integration.	Murray PJ.	海外	J Immunol. 2007;178(5):2623-9.
-	Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis.	Nam JL, Ramiro S, Gaujoux-Viala C, et al.	海外	Ann Rheum Dis. 2014;73(3):516-28.
-	Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection.	Namour F, Diderichsen PM, Cox E, et al.	海外	Clin Pharmacokinet. 2015;54(8):859–74.
-	Musculoskeletal syndromes associated with malignancy (excluding hypertrophic osteoarthropathy).	Naschitz JE, Rosner I.	海外	Curr Opin Rheumatol. 2008;20(1):100-05.
-	Pharmacokinetic interactions with rifampicin: clinical relevance.	Niemi M, Backman JT, Fromm MF.	海外	Clin Pharmacokinet. 2003;42(9):819–50.

第5部（モジュール5）　臨床試験報告書　添付資料一覧

5.4　参考文献

添付資料番号	タイトル	著者	報種類	掲載誌
-	Rheumatoid arthritis and birth outcomes: a Danish and Swedish nationwide prevalence study.	Norgaard M, Larsson H, Pedersen L, et al.	海外	J Intern Med. 2010;268(4):329-37.
-	Immunization to reduce the frequency and severity of herpes zoster and its complications.	Oxman, MN.	海外	Neurology. 1995;45 (12 Suppl 8):S41-6.
-	Alcohol consumption and risk of deep venous thrombosis and pulmonary embolism in older persons.	Pahor M, Guralnik JM, Havlik RJ, et al.	海外	J Am Geriatr Soc. 1996;44(9):1030-37.
-	Mortality and its predictors in patients with rheumatoid arthritis: a Danish population-based inception cohort study.	Pedersen JK, Holst R, Primdahl J, Svendsen AJ, Horslev-Petersen K.	海外	Scandinavian journal of rheumatology. 2018; 47: 371-7.
-	XELJANZ® (tofacitinib) tablets, for oral use XELJANZ® XR (tofacitinib) extended-release tablets, for oral use [package insert]. 2018	New York, NY; US Pfizer Laboratories	海外	-
-	Venous thromboembolism in patients with chronic obstructive pulmonary disease.	Piazza G, Goldhaber SZ, Kroll A, et al.	海外	Am J Med. 2012;125(10):1010-8.
-	Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized follow-up trial.	Puolakka K, Kautiainen H, Möttönen T, et al.	海外	Arthritis Rheum. 2004;50(1):55–62.

第5部（モジュール5）　臨床試験報告書　添付資料一覧

5.4　参考文献

添付資料番号	タイトル	著者	報種類	掲載誌
-	Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden.	Raaschou P, Simard JF, Asker Hagelberg C, et al.	海外	BMJ. 2016;352:1-8.
-	Risk of malignant neoplasm in patients with incident rheumatoid arthritis 1980–2007 in relation to a comparator cohort: a population-based study.	Raheel S, Crowson CS, Wright K, et al.	海外	Int J Rheumatol. 2016;2016:4609486.
-	Pregnancy outcomes in women with rheumatoid arthritis in Washington State.	Reed SD, Vollan TA, Svec MA.	海外	Matern Child Health J. 2006;10(4):361-6.
-	Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm.	Robertson J, Peters MJ, McInnes IB, et al.	海外	Nat Rev Rheumatol. 2013;9 (9): 513-23.
-	Incidence Estimate of Nonmelanoma Skin Cancer (Keratinocyte Carcinomas) in the U.S. Population, 2012.	Rogers HW, Weinstock MA, Feldman SR, et al.	海外	JAMA Dermatol. 2015;151(10):1081-6.
-	The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis.	Roubille C, Richer V, Starnino T, et al.	海外	Ann Rheum Dis. 2015;74(3):480-9.
-	Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review.	Rubbert-Roth A, Finckh A.	海外	Arthritis Res Ther. 2009;11 (Suppl 1):S1.

第5部（モジュール5）　臨床試験報告書　添付資料一覧

5.4　参考文献

添付資料番号	タイトル	著者	報種類	掲載誌
-	Environment, inflammation, and cancer.	Sansone P, Bromberg J.	海外	Curr Opin Genet Dev. 2011;21(1):80-5.
-	Incident myocardial infarction associated with major types of arthritis in the general population: a systematic review and meta-analysis.	Schieir O, Tosevski C, Glazier RH, et al.	海外	Ann Rheum Dis. 2017;76(8):1396-404.
-	Lymphopenia and autoimmune diseases.	Schulze-Koops H.	海外	Arthritis Res Ther 2004; 6:178-80.
-	Potential seminal transport of pharmaceuticals to the conceptus.	Scialli AR, Bailey G, Beyer BK, et al.	海外	Reprod Toxicol. 2015;58:213-21.
-	Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: how real is the risk?	Scott IC, Hider SL, Scott DL.	海外	Drug Saf. 2018;41:645-53.
-	Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers.	Seong SS, Choi CB, Woo JH, et al.	海外	J Rheumatol. 2007;34(4):706-11.
-	Review: cancer-induced autoimmunity in the rheumatic diseases.	Shah AA, Casciola-Rosen L, Rosen A.	海外	Arthritis Rheumatol. 2015;67(2):317-26.

第5部（モジュール5）　臨床試験報告書　添付資料一覧

5.4　参考文献

添付資料番号	タイトル	著者	報種類	掲載誌
-	Adverse reproductive outcomes in women who subsequently develop rheumatoid arthritis.	Silman AJ, Roman E, Beral V, et al.	海外	Ann Rheum Dis. 1988;47(12):979-81.
-	Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis.	Simon TA, Thompson A, Gandhi KK, et al.	海外	Arthritis Res Ther. 2015; 17 (212): 1-10.
-	2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.	Singh JA, Saag KG, Bridges SL Jr, et al.	海外	Arthritis Care Res. 2016;68(1):1–25.
-	Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors, and lymphoma characteristics.	Smedby E, Baecklund E, Askling J.	海外	Cancer Epidemiol Biomarkers Prev. 2006:15(11):2069-77.
-	Factors associated with preterm delivery among women with rheumatoid arthritis and juvenile idiopathic arthritis.	Smith CJF, Förger F, Bandoli G, et al.	海外	Arthritis Care Res (Hoboken). 2018.
-	The Risk of Herpes Zoster in Patients With Rheumatoid Arthritis in the United States and the United Kingdom.	Smitten AL, Choi HK, Hochberg MC, et al.	海外	Arthritis & Rheumatism. 2007;57(8):1431–38.
-	A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis.	Smitten AL, Simon TA, Hochberg MC, et al.	海外	Arthritis Res Ther. 2008;10(2):R45.

第5部（モジュール5）　臨床試験報告書　添付資料一覧

5.4　参考文献

添付資料番号	タイトル	著者	報種類	掲載誌
-	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.	Smolen JS, Landewe R, Bijlsma J, et al.	海外	Ann Rheum Dis. 2017;76(6):960-77.
-	Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment.	Smolen JS, Genovese MC, Takeuchi T, et al.	海外	J Rheumatol. 2018 Sep 15. [Epub ahead of print]
-	Mortality in rheumatoid arthritis: 2008 update.	Sokka T, Abelson B, Pincus T.	海外	Clin Exp Rheumatol. 2008;26 (5 Suppl 51):S35-61.
-	Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis.	Sokolove J, Strand V, Greenberg JD, et al.	海外	Ann Rheum Dis. 2010;69(9):1612-7.
-	Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis.	Solomon DH, Karlson EW, Rimm EB, et al.	海外	Circulation. 2003;107(9):1303–7.
-	Patterns of cardiovascular risk in rheumatoid arthritis.	Solomon DH, Goodson NJ, Katz JN, et al.	海外	Ann Rheum Dis. 2006;65(12):1608-12.
-	Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease modifying anti rheumatic drugs.	Solomon DH, Kremer JM, Fisher M, et al.	海外	Semin Arthritis Rheum. 2014;43(4):489-97.

第5部（モジュール5）　臨床試験報告書　添付資料一覧

5.4　参考文献

添付資料番号	タイトル	著者	報種類	掲載誌
-	Is poor pregnancy outcome a risk factor in rheumatoid arthritis?	Spector TD, Silman AJ.	海外	Ann Rheum Dis. 1990;49(1):12-4.
-	Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update.	Stoffer MA, Schoels, MM, Smolen JS, et al.	海外	Ann Rheum Dis. 2016;75(1):16–22.
-	Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic r conventional synthetic DMARDs.	Strangfeld A, Richter A, Siegmund B, et al.	海外	Ann Rheum Dis. 2017;76 (3): 504-10.
-	Risk of Herpes Zoster In Patients With Rheumatoid Arthritis Treated With Anti-TNF-Alpha Agents.	Strangfeld A, Listing J, Herzer P, et al.	海外	J Am Med Assoc. 2009. 301(7):737-744.
-	Lymphopenia in rheumatoid arthritis.	Symmons DP, Farr M, Salmon M, et al.	海外	J R Soc Med 1989; 82(8):462-3.
-	Longterm mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well.	Symmons DP, Jones MA, Scott DL, et al.	海外	J Rheumatol. 1998;25(6):1072-7.
-	Clinical features of liver dysfunction in collagen diseases.	Takahashi A, Yokokawa J, Iwadate H, et al.	海外	Hepatol Res.2010; 40(11):1092-97.

第5部（モジュール5）　臨床試験報告書　添付資料一覧

5.4　参考文献

添付資料番号	タイトル	著者	報種類	掲載誌
-	Baricitinib dose stepdown following disease control in patients with rheumatoid arthritis.	Takeuchi T., Genovese M., Xie L., et al.	海外	Ann Rheum Dis. 2016;75 (Suppl. 2):144.
-	Shortening of the QT interval after food can be used to demonstrate assay sensitivity in thorough QT studies.	Taubel J, Wong AH, Naseem A, et al.	海外	J Clin Pharmacol. 2012;52(10):1558-65.
-	Insulin at normal physiological levels does not prolong QT(c) interval in thorough QT studies performed in healthy volunteers.	Taubel J, Lorch U, Ferber G, et al.	海外	Br J Clin Pharmacol. 2013;75(2):392-403.
-	The reproducibility of QTc changes after meal intake.	Taubel J, Ferber G.	海外	J Electrocardiol. 2015;48(2):274-5.
-	Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis.	Taylor PC, Keystone EC, van der Heijde D, et al.	海外	N Engl J Med. 2017;367(7):652-62.
-	Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies.	Taylor PC, Kremer JM, Emery P, et al.	海外	Ann Rheum Dis. 2018;77(7):988-95.
-	Increased incidence of cardiovascular disease in patients with rheumatoid arthritis: results from a community based study.	Turesson C, Jarenros A, Jacobsson L.	海外	Ann Rheum Dis. 2004;63(8):952-5.

第5部（モジュール5）　臨床試験報告書　添付資料一覧

5.4　参考文献

添付資料番号	タイトル	著者	報種類	掲載誌
-	JAK inhibition for the treatment of rheumatoid arthritis: a new era in oral DMARD therapy.	Vaddi K, Luchi M.	海外	Expert Opin Investig Drugs. 2012;21(7):961-73.
-	The effectiveness of early treatment with “second-line” antirheumatic drugs. A randomized, controlled trial.	van der Heide A, Jacobs JW, Bijlsma JW, et al.	海外	Ann Intern Med. 1996;124(8):699–707.
-	How to read radiographs according to the Sharp/van der Heijde method.	van der Heijde D.	海外	J Rheumatol. 2000;27(1):261-3.
-	Tofacitinib, an oral janus kinase inhibitor, in combination with methotrexate reduced the progression of structural damage in patients with rheumatoid arthritis; year 2 efficacy and safety results from a 24-month Phase 3 study.	van der Heijde D, Tanaka Y, Fleischmann R, et al.	海外	Arthritis Rheum. 2012;64 (Suppl. 10):1277.
-	Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial.	van Dongen H, van Aken J, Lard LR, et al.	海外	Arthritis Rheum. 2007;56(5):1424–32.
-	Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease- modifying properties, and side effects.	Van Everdingen AA, Jacob JWG, Siewertsz van Reesema DR, et al.	海外	Ann Intern Med 2002;136:1-12
-	Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.	Van Vollenhoven RF, Fleischmann R, Cohen S, et al.	海外	N Engl J Med. 2012;367(6):508-19.

第5部（モジュール5）　臨床試験報告書　添付資料一覧

5.4　参考文献

添付資料番号	タイトル	著者	報種類	掲載誌
-	Incidence and time trends of herpes zoster in rheumatoid arthritis: a population-based cohort study.	Veetil BM, Myasoedova E, Matteson EL, et al.	海外	Arthritis Care Res. 2013;65(6):854–61.
-	Estimated pregnancy rates and rates of pregnancy outcomes for the United States, 1990 - 2008.	Ventura SJ, Curtin SC, Abma JC.	海外	Natl Vital Stat Rep. 2012;60(7):1-21.
-	Analysis of spontaneous postmarket case reports submitted to the FDA regarding thromboembolic adverse events and JAK inhibitors.	Verden A, Dimbil M, Kyle R, et al.	海外	Drug Saf. 2018;41(4):357-61.
-	Adherence to a treat-to-target strategy in early rheumatoid arthritis: results of the DREAM remission induction cohort.	Vermeer M, Kuper HH, Bernelot Moens HJ, et al.	海外	Arthritis Res Ther. 2012;14(6):R254.
-	Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial).	Verstappen SM, Jacobs JW, van der Veen MJ, et al.	海外	Ann Rheum Dis. 2007;66(11):1143-9.
-	Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register.	Verstappen SM, King Y, Watson KD, et al.	海外	Ann Rheum Dis. 2011;70(5):823-6.
-	Cardiovascular Morbidity and Mortality in Patients with Seropositive Rheumatoid Arthritis in Northern Sweden.	Wallberg-Jonsson S, Ohman M-L, Dahlqvist SR.	海外	J Rheumatol. 1997;24(3):445-51.

第5部（モジュール5）　臨床試験報告書　添付資料一覧

5.4　参考文献

添付資料番号	タイトル	著者	報種類	掲載誌
-	Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset.	Wallberg-Jonsson S, Johansson H, Ohman ML, et al.	海外	J Rheumatol. 1999;26(12):2562-71.
-	High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study.	Walldius G, Jungner I, Holme I, et al.	海外	Lancet. 2001;358(9298):2026–33.
-	Stroke mortality and the apoB/apoA-I ratio: results of the AMORIS prospective study.	Walldius G, Aastveit AH, Jungner I.	海外	J Intern Med. 2006;259(3):259–66.
-	Miscarriage and Stillbirth in Women with Rheumatoid Athritis.	Wallenius M, Salvesen KA, Daltveit AK, et al.	海外	J Rheumatol. 2015;42(9):1570-2.
-	Side effects of methotrexate therapy for rheumatoid arthritis: a systematic literature review.	Wang W, Zhou H, Liu L.	海外	Euro J Med Chem. 2018;158:502-16.
-	All-Cause Mortality and Vascular Events Among Patients with Rheumatoid Arthritis, Osteoarthritis, or No Arthritis in the UK General Practice Research Database.	Watson DJ, Rhodes T, Guess HA.	海外	J Rheumatol. 2003;30:1196-202.
-	A treat-to-target strategy preserves work capacity in a rheumatoid arthritis inception cohort treated with combination conventional DMARD therapy.	Wechalekar MD, Quinn S, Lester S, et al.	海外	J Clin Rheumatol. 2017;23(3): 131–7.

第5部（モジュール5）　臨床試験報告書　添付資料一覧

5.4　参考文献

添付資料番号	タイトル	著者	報種類	掲載誌
-	Cardiovascular safety during treatment with baricitinib in rheumatoid Arthritis [abstract].	Weinblatt M, Taylor PC, Burmester GR, et al.	海外	Arthritis Rheumatol. 2017;69 (suppl 10).
-	World Health Organization (WHO). Global tuberculosis control. WHO Report. Communicable diseases. Geneva. 2000	-	海外	-
-	Prevalence and Outcomes of Anemia in Rheumatoid Arthritis: A Systematic Review of the Literature.	Wilson A, Yu HT, Goodnough LT, et al.	海外	The American Journal of Medicine. 2004 (116): 50S-7S.
-	Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster.	Winthrop KL, Baddley JW, Chen L, et al.	海外	JAMA. 2013;309(9):887-95.
-	Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy.	Winthrop KL, Curtis JR, Lindsey S, et al.	海外	Arthritis & Rheumatology Vol. 69, No. 10, October 2017, pp 1960–68.
-	The emerging safety profile of JAK inhibitors in rheumatic disease.	Winthrop KL.	海外	Nat Rev Rheumatol. 2017;13(4):234-43.
-	The Mortality of Rheumatoid Arthritis.	Wolfe F, Mitchell DM, Sibley JT, et al.	海外	Arthritis Rheumatism 1994; 37 (4): 481-94.

第5部（モジュール5）　臨床試験報告書　添付資料一覧

5.4　参考文献

添付資料番号	タイトル	著者	報種類	掲載誌
-	The long term outcomes of rheumatoid arthritis: Work disability: a prospective 18 year study of 823 subjects.	Wolfe F, Hawley DJ.	海外	J Rheumatol. 1998;25(11):2108-17.
-	Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies.	Wollenhaupt J, Silverfield J, Lee EB, et al.	海外	J Rheumatol. 2014;41(5):837-52.
-	Brief report: risk of gastrointestinal perforation among rheumatoid arthritis patients receiving tofacitinib, tocilizumab, or other biologic treatments.	Xie F, Yun H, Bernatsky S, et al.	海外	Arthritis Rheumatol. 2016;68 (11):2612-17.
-	Physiologically Based Pharmacokinetic Model to Assess the Influence of Blinatumomab-Mediated Cytokine Elevations on Cytochrome P450 Enzyme Activity.	Xu Y, Hijazi Y, Wolf A, et al.	海外	CPT Pharmacometrics Syst Pharmacol. 2015;4(9):507–15.
-	Estimates of the prevalence of and current treatment practices for rheumatoid arthritis in Japan using reimbursement data from health insurance societies and the IORRA cohort (I).	Yamanaka H, Sugiyama N, Inoue E, et al.	国内	Mod Rheumatol. 2014;24:33-40.
-	Benefit and risk of tofacitinib in the treatment of rheumatoid arthritis: a focus on herpes zoster.	Yamaoka K.	海外	Drug Saf. 2016;39(9):823-40.
-	Modeling of rifampicin-induced CYP3A4 activation dynamics for the prediction of clinical drug-drug interactions from in vitro data.	Yamashita F, Sasa Y, Yoshida S, et al.	海外	PLoS One. 2013;8(9):e70330.

第5部（モジュール5）　臨床試験報告書　添付資料一覧

5.4　参考文献

添付資料番号	タイトル	著者	報種類	掲載誌
-	A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction.	Yawn BP, Saddier P, Wollan PC, et al.	海外	Mayo Clinic Proc. 2007;82(11):1341–9.
-	Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis.	Young A, Koduri G, Batley M, et al.	海外	Rheumatology. 2007;46(2):350-7.
-	Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.	Yusuf S, Hawken S, Ounpuu S, et al.	海外	Lancet. 2004;364(9438):937–52.
-	Cardiovascular risk in rheumatoid arthritis: assessment, management and next steps.	Zegkos T, Kitas G, Dimitroulas T.	海外	Ther Adv Musculoskelet Dis 2016; 8(3): 86-101
-	Impact on creatinine renal clearance by the interplay of multiple renal transporters: a case study with INCB039110.	Zhang Y, Warren MS, Zhang X, et al.	海外	Drug Metab Dispos. 2015 Apr;43(4):485-9.
-	Hypertension associated with venous thromboembolism in patients with newly diagnosed lung cancer.	Zhang Y, Yang Y, Chen W, et al.	海外	Sci Rep. 2016;6:19603.
-	Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study.	Zhao P, Ragueneau- Majlessi I, Zhang L, et al.	海外	J Clin Pharmacol. 2009;49(3):351–9.